Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line


06 Mar 2023


Cocktail & Poster Display session


Heloise Beutier


Annals of Oncology (2023) 8 (1suppl_2): 100896-100896. 10.1016/esmoop/esmoop100896


H. Beutier

Author affiliations

  • Hoddesdon En11 9fh, Pharmaron UK, NN10 6ER - Rushden/GB


This content is available to ESMO members and event participants.

Abstract 68P


Deregulation of the cyclin D-CDK4/6-INK4-RB pathway leading to uncontrolled increased cell proliferation, is observed in various cancer types including breast cancer. Palbociclib is one of the selective CDK4/6 inhibitors approved for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Despite initial response to Palbociclib, intrinsic or acquired resistance emerges eventually. Understanding resistance mechanisms to CDK4/6 inhibitors enables us to design drug combination regimen to overcome or delay resistance onset, to identify biomarkers to predict therapy outcome that can be utilized to stratify patients who benefit from the treatment and to identify novel druggable targets in the CDK4/6 drug resistance milieu.


To investigate proteome alterations leading to Palbociclib resistance, we established resistant sublines of MCF7 breast cancer cell line by culturing the cells in a) under constant pressure of 1uM Palbociclib and b) in drug holiday after 1uM Palbociclib for several cycles. We then performed RPPA (Reverse Phase Protein Array) technology to analyse 384 protein targets in the two groups compared to parental Palbociclib sensitive MCF7 cells as well as comparing the two resistant sublines.


Pathways analyses in sensitive vs. resistance cells showed significant changes in cell cycle dependent and independent pathways including EGFR pathway, p53 pathway, and the JAK-STAT signalling pathways.


These pathways are closely related to the occurrence, development, and metastasis of cancer. Drugs that target these pathways may provide new strategies for combination therapies in Palbociclib-resistant patients. Also, to validate the proteome alterations, we will perform RNAseq analysis on the cell line pairs to investigate whether the proteome alteration is observed at transcriptome level.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study





The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.